PHASE I STUDY OF GDC-0919 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER DRUGS IN PATIENTS WITH ADVANCED SOLID TUMORS

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223275

Enrollment

Registered

2016-07-28

Start date

2016-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

investigational material(s) Generic name etc : GDC-0919/RG6078 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -ECOG Performance Status of 0 or 1 -Histologically or cytologically documented solid tumors -Evaluable lesion by image

Exclusion criteria

Exclusion criteria: -Inability to take oral drugs -Meningeal metastasis or metastasis to the central nervous system requiring treatment or accompanied by symptoms -History or complication of autoimmune disease

Design outcomes

Primary

Measure	Time frame
Safety, tolerability, and pharmacokinetics Observation/test	—

Secondary

Measure	Time frame
Anti-tumor activity Observation/test	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026